Tazobactam Sodium/Ceftolozane

他唑巴坦钠/头孢洛生

Report date: 2025/02/14 17:13:13
QIDP

Base Information

Drug NameTazobactam Sodium/Ceftolozane
Drug Alias Name头孢洛生他唑巴坦钠CXA-101/tazobactamTazobactam/CXA-101Ceftolozane/TazobactamTazobactam/Ceftolozane +[11] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > β-lactam antibiotics > Cephalosporins antibiotics
Mechanisms of ActionPenicillin-binding protein 3 inhibitorsPenicillin-binding protein 1b inhibitorsBeta Lactamase inhibitors
TargetsBeta LactamasePenicillin-binding protein 1bPenicillin-binding protein 3
Therapy Area/IndicationsHospital-acquired pneumoniaCommunity-acquired bacterial pneumoniaCritical Illness +[17] 
Global Approved IndicationsCommunity-acquired bacterial pneumoniaCystitisPyelonephritis +[9] 
Approved Indications in ChinaCommunity-acquired bacterial pneumoniaPyelonephritisUrinary Tract Infections +[5] 
Original Approved Country/TerritoryUnited States
Original Approved Date2014/12/19
Country/TerritoryBulgariaUnited StatesUkraine +[32] 
CombinationsYes Tazobactam SodiumCeftolozane
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMerck Sharp & Dohme BvCubist Pharmaceuticals Llc +[4] 
Inactive CompaniesSteri-Pharma LlcMerck Sharp & Dohme LtdMSD R&D（China）Co Ltd
Active IndicationsHospital-acquired pneumoniaCommunity-acquired bacterial pneumoniaCystitis +[12] 
Inactive IndicationsCritical IllnessDiabetes MellitusLung Diseases +[5] 

Other Information

ATC CodeJ01
Related LinksKEGG